| Adrian Alonso Ochoa, MD | |
|
525 E Market St, Akron, OH 44304-1619 | |
| (330) 375-3588 | |
| (330) 375-7615 |
| Full Name | Adrian Alonso Ochoa |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 11 Years |
| Location | 525 E Market St, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023451846 | NPI | - | NPPES |
| 0122241 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 35.131488 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Summa Health System | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Americare Kidney Institute Llc | 9133356843 | 23 |
| Summa Physicians Inc | 2961303532 | 640 |
News Archive
Vaccination may be the most effective public health intervention of all time-especially in low-income countries, where many families can't access or afford health care when they are sick. On Friday, January 29, speaking at the World Economic Forum in Davos, Switzerland, Bill and Melinda Gates announced a new ten-year Gates Foundation commitment to funding vaccine development and delivery.
A Democratic House member grapples with the troubles in the health law rollout. CBO releases numbers on adding Capitol Hill staffers to the exchanges and a House committee ponders subpoenas to get exchange enrollment numbers. Also, Sen. Lindsey Graham, R-S.C., readies a bill that would ban abortions after 20 weeks of pregnancy.
CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.
The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.
Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.
› Verified 5 days ago
| Entity Name | Summa Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235167719 PECOS PAC ID: 2961303532 Enrollment ID: O20040116000295 |
News Archive
Vaccination may be the most effective public health intervention of all time-especially in low-income countries, where many families can't access or afford health care when they are sick. On Friday, January 29, speaking at the World Economic Forum in Davos, Switzerland, Bill and Melinda Gates announced a new ten-year Gates Foundation commitment to funding vaccine development and delivery.
A Democratic House member grapples with the troubles in the health law rollout. CBO releases numbers on adding Capitol Hill staffers to the exchanges and a House committee ponders subpoenas to get exchange enrollment numbers. Also, Sen. Lindsey Graham, R-S.C., readies a bill that would ban abortions after 20 weeks of pregnancy.
CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.
The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.
Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.
› Verified 5 days ago
| Entity Name | Americare Kidney Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013349471 PECOS PAC ID: 9133356843 Enrollment ID: O20131227001669 |
News Archive
Vaccination may be the most effective public health intervention of all time-especially in low-income countries, where many families can't access or afford health care when they are sick. On Friday, January 29, speaking at the World Economic Forum in Davos, Switzerland, Bill and Melinda Gates announced a new ten-year Gates Foundation commitment to funding vaccine development and delivery.
A Democratic House member grapples with the troubles in the health law rollout. CBO releases numbers on adding Capitol Hill staffers to the exchanges and a House committee ponders subpoenas to get exchange enrollment numbers. Also, Sen. Lindsey Graham, R-S.C., readies a bill that would ban abortions after 20 weeks of pregnancy.
CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.
The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.
Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adrian Alonso Ochoa, MD 525 E Market St # I, Akron, OH 44304-1619 Ph: (330) 375-3388 | Adrian Alonso Ochoa, MD 525 E Market St, Akron, OH 44304-1619 Ph: (330) 375-3588 |
News Archive
Vaccination may be the most effective public health intervention of all time-especially in low-income countries, where many families can't access or afford health care when they are sick. On Friday, January 29, speaking at the World Economic Forum in Davos, Switzerland, Bill and Melinda Gates announced a new ten-year Gates Foundation commitment to funding vaccine development and delivery.
A Democratic House member grapples with the troubles in the health law rollout. CBO releases numbers on adding Capitol Hill staffers to the exchanges and a House committee ponders subpoenas to get exchange enrollment numbers. Also, Sen. Lindsey Graham, R-S.C., readies a bill that would ban abortions after 20 weeks of pregnancy.
CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.
The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.
Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.
› Verified 5 days ago
Dr. Michael A Pelini, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St, Ste 300, Akron, OH 44304 Phone: 330-376-7000 Fax: 330-376-1066 | |
David P. Lang, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 4125 Medina Rd, #200c, Akron, OH 44333 Phone: 330-665-8031 Fax: 330-665-8360 | |
Ms. Tiffany Mccann, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3561 | |
Jonathan Buggey, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St Ste 300, Akron, OH 44304 Phone: 724-422-6808 | |
Shamsa Baaj, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Mira Rohit Patel, DO Nephrology Medicare: Medicare Enrolled Practice Location: 161 N Forge St Ste 198, Akron, OH 44304 Phone: 330-375-3039 | |
Richard J Streck, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, 5th Floor Ambulatory Care Center, Akron, OH 44307 Phone: 330-344-6015 Fax: 330-344-6820 |